Patient Guide: Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • Get matched to the right study location for you
  • Connect directly with study coordinators at 9 participating sites
  • Understand eligibility with our simplified screening tool
  • Free service - we're here to help you access clinical research
Trial ID: NCTNCT06784648
Status: ACTIVE_NOT_RECRUITING
Condition: Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated, Melanoma Recurrent, Melanoma Stage III or IV, Melanoma, Melanoma Negative for bRAF, Melanoma Negative for nRAS, Melanomas, Uveal Melanoma, Metastatic
Phase: PHASE1, PHASE2

Find a Study Location Near You

This study is available at 9 research sites. We'll help you connect with the location that's right for you.

Participating sites include:
  • Berlin,
  • Essen,
  • Heidelberg,
  • • And 6 more locations - let us help you find the closest one

Loading interactive enrollment tools...

The full interactive experience will load momentarily